|
SU6668 in Treating Patients With Advanced Solid Tumors Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about SU6668 in Treating Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. SU6668 in Treating Patients With Advanced Solid Tumors Clinical research trials and SU6668 in Treating Patients With Advanced Solid Tumors medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as SU6668 in Treating Patients With Advanced Solid Tumors. SU6668 in Treating Patients With Advanced Solid Tumors Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a SU6668 in Treating Patients With Advanced Solid Tumors clinical trial. Subjects often receive the most expert healthcare possible for their SU6668 in Treating Patients With Advanced Solid Tumors condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > SU6668 in Treating Patients With Advanced Solid Tumors  SU6668 in Treating Patients With Advanced Solid Tumors
SU6668 in Treating Patients With Advanced Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , M.D. Anderson Cancer Center
Synopsis: RATIONALE: SU6668 may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU6668 in treating patients who have advanced solid tumors.
Details: OBJECTIVES: I. Determine the optimal biologically effective dose of SU6668 in patients with advanced solid tumors. II. Assess the safety and tolerability of this therapy in these patients. III. Determine the pharmacokinetic profile and interpatient pharmacologic variability of this therapy in these patients. IV. Determine the extent, frequency, and duration of any tumor responses in patients treated with this therapy. V. Determine a recommended phase II dose of SU6668 for future clinical studies. PROTOCOL OUTLINE: This is a dose-escalation study. Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more. Cohorts of at least 6 patients receive escalating doses of SU6668 until the optimal biologically effective dose (OBD) is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed advanced solid tumor for which no standard therapy exists - At least 1 measurable tumor lesion (at least 2 cm) not previously irradiated - No history of brain metastases; Negative brain CT/MRI required for patients with signs and symptoms suspicious for brain metastases --Prior/Concurrent Therapy-- - Biologic therapy: At least 30 days since prior over-the-counter, anticancer biologic agents (e.g., shark cartilage); No concurrent over-the-counter, anticancer biologic agents (e.g., shark cartilage) - Chemotherapy: At least 3 weeks since prior cytotoxic or cytostatic agents (6 weeks for nitrosoureas or mitomycin); Patients with ECOG performance status 0: Any number of prior chemotherapy regimens allowed; Patients with ECOG performance status 1: No more than 3 prior chemotherapy regimens for metastatic or recurrent disease; The same drug given on a different schedule does not count as a different regimen Prior adjuvant chemotherapy for nonmetastatic disease or as part of a concurrent chemoradiotherapy protocol is allowed but does not count as part of the 3-regimen limit - Endocrine therapy: Not specified - Radiotherapy: See Disease Characteristics; See Chemotherapy; At least 3 weeks since prior radiotherapy to nonindicator lesions; No concurrent radiotherapy - Surgery: At least 24 hours since prior minor surgery (e.g., central venous catheter placement); At least 4 weeks since prior major surgery (e.g., laparotomy, thoracotomy, or craniotomy) - Other: At least 30 days since prior anticancer herbal remedies; At least 30 days since prior investigational agents; No concurrent anticancer herbal remedies; No other concurrent investigational or anticancer medication --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-1 - Life expectancy: Not specified - Hematopoietic: WBC greater than 3,000/mm3; Absolute neutrophil count greater than 1,500/mm3; Platelet count greater than 100,000/mm3; Hemoglobin greater than 10 g/dL; No history of bleeding diathesis - Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN); ALT less than 2.5 times ULN - Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min - Other: No concurrent uncontrolled medical or psychiatric disorders; No severe iodine allergy; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RoyHerbst, Study Chair, M.D. Anderson Cancer Center
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Additional Information:
Study ID Numbers: CDR0000068900; MDA-ID-00184,NCI-1017
Study Start Date: July 2001
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00024206
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
2. Combination Chemotherapy in Treating Patients With Advanced Cancer
3. BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
4. Buspirone in Reducing Shortness of Breath in Patients With Cancer
5. Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
SU6668 in Treating Patients With Advanced Solid Tumors
|
|
|
|
|
|
|
|
